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ABSTRACT
Objective: To report 14 patients with immune-mediated relapsing symptoms post–herpes simplex
encephalitis (HSE) and to compare the clinical and immunologic features of the teenage and adult
group with those of young children.
Methods: Prospective observational study of patients diagnosed between June 2013 and
February 2015. Immunologic techniques have been reported previously.
Results: Among the teenage and adult group (8 patients, median age 40 years, range 13–69; 5
male), 3 had an acute symptom presentation suggesting a viral relapse, and 5 a presentation
contiguous with HSE suggesting a recrudescence of previous deficits. Seven patients developed
severe psychiatric/behavioral symptoms disrupting all social interactions, and one refractory sta-
tus epilepticus. Blepharospasm occurred in one patient. Five patients had CSF antibodies against
NMDA receptor (NMDAR) and 3 against unknown neuronal cell surface proteins. In 5/6 patients,
the brain MRI showed new areas of contrast enhancement that decreased after immunotherapy
and clinical improvement. Immunotherapy was useful in 7/7 patients, sometimes with impressive
recoveries, returning to their baseline HSE residual deficits. Compared with the 6 younger chil-
dren (median age 13 months, range 6–20, all with NMDAR antibodies), the teenagers and adults
were less likely to develop choreoathetosis (0/8 vs 6/6, p , 0.01) and decreased level of con-
sciousness (2/8 vs 6/6, p , 0.01) and had longer delays in diagnosis and treatment (interval
relapse/antibody testing 85 days, range 17–296, vs 4 days, range 0–33, p 5 0.037).
Conclusion: In teenagers and adults, the immune-mediated relapsing syndrome post-HSE is different
from that known in young children as choreoathetosis post-HSE and is underrecognized. Prompt diag-
nosis is important because immunotherapy can be highly effective. Neurology® 2015;85:1736–1743
GLOSSARY
FLAIR 5 fluid-attenuated inversion recovery; HSE 5 herpes simplex virus encephalitis; HSV 5 herpes simplex virus;
IDIBAPS 5 Institute of Biomedical Research August Pi i Sunyer; IgG 5 immunoglobulin G; IQR 5 interquartile range;
IVIg 5 IV immunoglobulin; NMDAR 5 NMDA receptor.
Herpes simplex virus (HSV) encephalitis (HSE) is a frequent cause of severe, potentially fatal
encephalitis among children and adults worldwide. The disease usually follows a monophasic
course but 12%–27% of the patients develop relapsing neurologic symptoms a few weeks after
the CSF viral studies become negative and the treatment with acyclovir has been discontinued.1–3
Most of these patients are children who develop an encephalopathy with abnormal movements
named choreoathetosis post-HSE or relapsing symptoms post-HSE.4 The hypothesis that the
disorder is immune-mediated has received strong support by the recent discovery that many of
these patients develop immunoglobulin G (IgG) antibodies against the GluN1 subunit of the
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NMDA receptor (NMDAR)5–11 and some-
times to other known7 or unknown synaptic
proteins.6 This clinical complication is less
well-known in adults and teenagers, suggesting
a lower frequency in these age groups or a dif-
ferent and less recognizable syndrome. Over
the last 21 months, we have prospectively iden-
tified 14 new patients with relapsing symptoms
post-HSE, 8 of them adults or teenagers. In the
current study, we show that the clinical picture
of these patients is indeed different from that of
young children with choreoathetosis, leading to
delays in diagnosis and treatment. Prompt rec-
ognition of this disorder is important because
immunotherapy is effective in reducing the
burden of the immune-mediated deficits and
improving the quality of life of patients and
families.
METHODS From June 2013 until February 2015, serum and
CSF of 14 patients with nonviral relapsing symptoms post-HSE
were prospectively studied at the Institute of Biomedical Research
August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of
Barcelona. Five of the patients (patients 3, 5, 8–10) were
examined as part of a 2-year multicenter prospective Spanish
study in which all patients with HSE are clinically and
immunologically followed after being diagnosed with HSE. The
other 9 patients were diagnosed either before this multicenter
HSE study was initiated (January 1, 2014, patients 1, 4, 12) or
at centers that do not participate in the study (2 from Spain, 4
from other countries). In the prospective multicenter study,
physicians are blinded to the immunologic findings unless
patients develop relapsing symptoms. Of 20 patients with
HSE (6 children and 14 adults) enrolled to date, the
indicated 5 cases (25%) have developed relapsing neurologic
symptoms post-HSE.
CSF or serum of all patients were extensively examined for anti-
bodies to cell surface/synaptic proteins, including NMDA,
mGluR5, AMPA, GABAB, GABAA, D2 receptors, LGI1, Caspr2,
and DPPX, using previously reported techniques that included tis-
sue immunohistochemistry, live cultured neurons, and cell-based
assays.12–16 All patients underwent repeat CSF PCR for HSV and
MRI of the brain (9 with contrast and 5 without). Clinical infor-
mation was obtained by the authors or from referring physicians. No
data of any patient have been reported previously.
Standard protocol approvals, registrations, and patient
consents. Written informed consent for participating in the
study was obtained from all patients or guardians of patients.
Studies were approved by the internal review board of Hospital
Clinic-IDIBAPS and the ethical standards committee on
human experimentation of IDIBAPS.
Statistical analysis. Comparative analyses between the group of
teenagers and adults and the group of children were performed
with STATA version 13.1 (StataCorp, College Station, TX),
using Fisher exact test, x2 test, or Mann-Whitney U test when
appropriate. The Wilcoxon rank-sum test was used for
comparative studies between the CSF obtained during the stage
of viral encephalitis and that obtained during the autoimmune
relapse.
RESULTS Eight of the 14 patients with nonviral
relapsing neurologic symptoms post-HSE were
adults or teenagers (median age 40 years, range 13–
69; 5 male) and the other 6 were young children
(median age 13 months, range 6–20 months; 3
male). Repeat CSF PCR for HSV was negative in all
patients. The 6 young children developed a classical
syndrome of choreoathetosis post-HSE in association
with IgG antibodies against the GluN1 subunit of the
NMDAR and one of them also had antibodies against
the GABAAR (figure e-1 on the Neurology® Web site at
Neurology.org). In many respects, these children were
clinically similar to previously reported cases and are not
the focus of this study (see information in table e-1,
patients 9–14). In contrast, the 8 patients in the teenage
and adult group did not develop choreoathetosis and are
the main focus of this report (table 1, patients 1–8, and
clinical vignettes in supplemental material).
In these 8 patients, the onset of relapsing symptoms
started 12–51 days (median 39, interquartile range
[IQR] 26–43 days) after onset of HSE. In 3 patients
(2–4), symptoms presented acutely, mimicking a viral
relapse (biphasic course), and all 3 patients were re-
started on acyclovir along with antipsychotic drugs or
benzodiazepines while waiting for the results of repeat
CSF PCR studies. In the other 5 patients (1, 5–8), the
symptoms developed while recovering in rehabilitation
centers or at home, or in contiguity with those of HSE,
without a clear biphasic stage, and none of the patients
was initially considered to have relapsing symptoms. In
these patients, the symptoms were initially attributed
to a recrudescence of residual viral-related deficits and
managed with antipsychotics and antidepressants. The
severity and persistence of neuropsychiatric symptoms
eventually led to reconsideration of the possibility of an
independent complication. Three of these patients (3,
5, and 8) were diagnosed with immune-mediated
symptoms when they returned for a routine outpatient
visit as part of the prospective study.
Seven patients presented with acute or subacute
change of behavior, agitation, aggression, suicidal idea-
tion, confusion, or delusional thoughts, and one
patient with refractory seizures and status epilepticus
requiring mechanical ventilation and barbiturate coma
(patient 6). An example of the severe alteration of men-
tal functions and imaginary graphic representation is
shown in the drawings of patient 8 (figure 1). In 3
patients (patients 1, 3, and 4), the neuropsychiatric
manifestations were heralded by intense headache,
accompanied in one case by drug-resistant high blood
pressure (table 1, and case vignettes in supplemental
data). In another patient (patient 7), the change of
behavior was followed a few days later by fever,
decreased level of consciousness, and severe blepharo-
spasm. Except for this case, no abnormal movements
were identified in the other patients.
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Table 1 Clinical features of adults and teenagers with autoimmune relapsing symptoms post–herpes simplex encephalitis
Patient/
sex/
age, y
HSE Autoimmune relapse
Symptoms Brain MRI
CSF and
immunologic studies
Treatment and
response Symptoms Brain MRI CSF and immunologic studies Treatment Outcome
1/M/13 Fever, seizures,
aphasia,
cardiorespiratory
arrest
D2: left FT, right FB
necrotic lesions
with ADC restr
D5: HSV pos; D23:
HSV neg, WBC 27,
prot 51, neg NSAb
IV Acyc (21 d);
motor and cognitive
residual deficits
D42: aggressive
behavior, headache,
high blood pressure
D186: no new
necrosis, [ WM
changes, contrast:
NA
D178: HSV neg, WBC 7, prot#45,
NMDAR Ab (1:160) (also in serum
1:800)
D45: Risperidone,
high blood pressure
drugs; D190: IV MP
Partial improvement of
behavioral deficits, FU
15 mo, motor and
cognitive deficits
2/M/15 Headache, focal
seizures,
encephalopathy
D3: bilateral FT
necrosis 1 ADC
restr, no enhanc
D2: HSV pos, WBC 2,
prot 50
IV Acyc (21 d);
complete recovery
D51: agitation,
cognitive deficits,
aggressive behavior
D69: no new
necrosis,[ WM
changes, enhanc 1
D62: HSV neg, WBC 0, prot #45,
pos OCB, NMDAR Ab (1:80);
D102: NMDAR Ab (1:20)
D60: Acyc, lorazepam;
D102: IV MP, oral MP,
IVIg
Rapid resolution of
behavior abnormalities,
FU 12 mo, complete
recovery
3/M/45 Headache, fever,
confusion,
aphasia
D10: left T
necrosis 1 ADC
restr, mild enhanc;
D23: no changes
D10: HSV pos, WBC
110, prot 74; D25:
HSV neg, WBC 56,
prot 78
IV Acyc (21 d);
residual global
aphasia
D44: headache,
confusion, agitation,
delusional thoughts,
insomnia
D51: no new
necrosis,[ WM
changes; enhanc 11;
D141: enhanc 1
D44: HSV neg, WBC 5, prot 93;
D145: HSV neg, WBC 10, prot 43,
pos OCB, NMDAR Ab (1:40)
D44: Acyc (5 d),
alprazolam
Relapsing symptoms that
faded spontaneously, FU
6 mo, residual aphasia
4/M/50 Fever, aphasia,
memory deficits
D2: bilateral T
necrosis 1 ADC
restr, no enhanc
D2: HVS pos, WBC
239, prot 66
IV Acyc (14 d); good
recovery
D40: headache,
aggression, suicidal
ideation, tremor,
sleep disorder
D86: no new
necrosis, [ WM
changes, enhanc 1;
D360: enhanc 111
D86: HSV neg, WBC 27, prot 107;
D336: WBC 15, prot 88, NMDAR
Ab (1:2); D585: HSV neg, WBC 7,
prot 80
D86: Acyc (14 d),
risperidone; D392:
MP, IVIg; D586:
starting RTX, CYC
Improvement of
behavioral symptoms, FU
20 mo, moderate
behavioral deficits
5/F/34 Fever, focal
seizures, aphasia,
memory deficits
D2: left T
necrosis 1 ADC
restr, enhanc NA
D2: HSV pos, WBC
460, prot 51, neg
NSAb
IV Acyc (14 d);
persistent aphasia
and memory deficits
D38: insomnia,
anxiety, restlessness,
irritability, delusions
D65: no new
necrosis, [ WM
changes, no enhanc
D60: HSV neg, WBC 10, prot 65,
NMDAR Ab (1:80) (also in serum
1:400)
D60: IV MP Improvement of
behavior, FU 2 mo, mild
aphasia and memory
deficits
6/F/69 Speech problems,
confusion, fever,
partial seizures
D2: normal brain CT D2: HSV pos, WBC
32, prot #45
IV Acyc (21 d);
improvement of
seizures after 6
days of treatment
D12: confusion, new-
onset nonconvulsive
status epilepticus
D8: left T cortical and
WM changes, no ADC
restr, enhanc 11
D29: HSV neg, WBC 0, prot #45,
pos NSAb (also in serum)
D12: Acyc,
barbiturate coma;
D29: MP, IVIg, PEX;
D60: RTX
Transient response to
PEX, seizure control
post-RTX, FU 3 mo, mild
aphasia
7/M/29 Fever, respiratory
failure, seizures,
abnormal
behavior
D3: right FT
hypointensity in CT
D2: HSV pos, WBC
49, prot 60
IV Acyc (13 d);
motor and cognitive
residual deficits
D21: abnormal
behavior; D60: fever,
Y consciousness,
blepharospasm
D70: no new
necrosis, bilateral FT
WM changes, enhanc
NA
D58: HSV neg, WBC 2, prot 112;
D90: HSV neg, WBC 12, prot 63,
pos NSAb
D15: Acyc (21 d),
haloperidol,
risperidone; D100:
IV MP
Improvement after MP
and local Botox, FU 12
mo, minor deficits (back
to work)
8/F/56 Fever, diarrhea,
somnolence,
catatonia
D7: bilateral T
necrosis, no ADC
restr, no enhanc
D7: HSV pos, WBC
250, prot 62; D21:
HSV neg, WBC 90,
prot 61
IV Acyc (15 d);
residual
anterograde
amnesia
D30: emotional
lability, suicidal
ideation, confusion
D150: no new
necrosis, [ WM
changes, enhanc 11;
D314: no enhanc
D146: HSV neg, WBC 10, prot 45,
pos OCB, pos NSAb (neg serum)
D30: quetiapine,
citalopram,
paroxetine; D160:
IV MP
Improvement in
psychiatric symptoms,
FU 15 mo, anterograde
amnesia
Abbreviations: Ab 5 antibodies; Acyc 5 acyclovir; ADC restr 5 apparent diffusion coefficient restriction; CYC 5 cyclophosphamide; enhanc 5 contrast enhancement; FB 5 frontobasal; FT 5 frontotemporal; FU 5
follow-up; HSE 5 herpes simplex virus encephalitis; HSV 5 herpes simplex virus; IVIg 5 IV immunoglobulin; MP 5 methylprednisolone; NA 5 not available; neg 5 negative; NMDAR 5 NMDA receptor; NSAb 5
neuronal surface antibodies (unknown identity); OCB5 oligoclonal bands; PEX5 plasma exchange; pos5 positive; prot5 CSF total protein in mg/dL; RTX5 rituximab; T5 temporal; WBC5white blood cell count/mL
in CSF; WM 5 white matter.
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The median time between onset of relapsing symp-
toms and CSF routine and viral studies was 30 days
(IQR 14–81, range 0–136), and for antibody testing
85 days (IQR 37–126, range 17–296). The PCR for
HSV was negative in all 8 patients. Five patients had
pleocytosis (median 10 leukocytes, IQR 7–10, range
5–27) and 4 had increased protein concentration
(median 100 mg/dL, IQR 79–110). The level of ple-
ocytosis was substantially lower than that previously
found during the viral encephalitis (median 80 leuko-
cytes, IQR 30–245, range 2–460, p , 0.01). Patients
1–5 had IgG antibodies against the GluN1 subunit of
the NMDAR (all 5 in CSF, 2 also in serum; figure 2
and figure e-2); patients 6–8 had antibodies against
unknown neuronal antigens (all 3 in CSF, 1 also in
serum). Archived CSF and serum obtained at the time
of the HSE were available in 4 patients (patients 1, 3,
5, and 7) and all were negative for NMDAR or other
autoantibodies (figure e-2).
All 8 patients underwent brain MRI; 6 had prior
MRI studies obtained by the time of HSE, and the
other 2 had CT scans (patients 6 and 7). In the 6 pa-
tients with repeat MRI, this showed mild to moderate
interval progression of T2/fluid-attenuated inversion
recovery (FLAIR) abnormalities compared with that
obtained during HSE (figure 3, A–D). Gadolinium
was used in 6 of the 8 patients at symptom relapse,
showing in 5 contrast enhancement (4 intense,
1 mild) in the same areas with T2/FLAIR abnormal-
ities (figure 3, F, G, and L). In 4 cases, the findings
could be compared with those of the MRI obtained
during HSE, which showed absence or mild enhance-
ment. Several additional follow-up MRIs were ob-
tained in 3 patients; 2 of them showed dramatic
reduction or absence of contrast enhancement after
clinical improvement (patients 3 and 8, figure 3H),
and the third patient, who had not received immu-
notherapy and continued with severe deficits, showed
persistent contrast enhancement 1 year after onset of
relapsing symptoms (patient 4, figure 3L).
Before immunotherapy, 6 patients (patients 1, 2, 4,
6–8) received acyclovir, antipsychotics, or antidepres-
sants, and all continued to deteriorate: 5 developed
drug-resistant psychiatric symptoms (one of them,
patient 7, progressing to coma), and 1 developed
refractory status epilepticus needing barbiturate coma.
Only one patient (patient 3) improved without immu-
notherapy (described below).
Figure 1 Drawings by patient 8 at presentation of relapsing symptoms post–herpes simplex virus encephalitis
and after immunotherapy
Drawings by patient 8 at the time of relapsing symptoms (tree, family, and house, A, D, and G), 3 weeks after immunotherapy
(B, E, H), and at a 6 months follow-up (C, F, I). At presentation of relapsing symptoms, the patient had severe anterograde
amnesia, confusion, disorganized thoughts, and disorientation to place, time, and person. After immunotherapy, her
symptoms resolved except for amnesia and temporal orientation.
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The median time between onset of relapsing symp-
toms and immunotherapy was 79 days (IQR 22–148,
range 17–352 days). This included steroids in 4 pa-
tients, steroids and IV immunoglobulin (IVIg) in 1,
and steroids, IVIg, and plasma exchange in the other 2
patients. In all 7 cases, a substantial improvement was
noted after the immunotherapy was started. At last
follow-up (median 12 months, IQR 4.5–15, range
2–20 months), 2 patients had full or near complete
recovery (patients 2 and 6), and the other 5 had sub-
stantial improvement of the neuropsychiatric abnor-
malities or seizures, returning to their baseline
residual deficits of HSE (table 1 and supplemental case
vignettes). The patient with refractory status epilepti-
cus improved transiently after the first plasma exchange
but because of recurrent electrographic seizures he was
started on IVIg and rituximab. This treatment resulted
in complete seizure control and improved level of con-
sciousness, but he was left with HSE-related residual
aphasia and critical illness neuropathy.
The patient who was not treated with immuno-
therapy (patient 3, table 1 and case vignettes in sup-
plemental data) was tested for antibodies 3 months
after the neurologic relapse as part of the prospective
multicenter study of patients with HSE. This patient
on day 40 post-HSE developed agitation, delusional
thoughts, and insomnia that improved with alprazo-
lam. By the time he was found to have NMDAR
antibodies in CSF (serum negative), his symptoms
had substantially improved and the contrast enhance-
ment in the MRI had decreased.
When the clinical features of these 8 teenagers and
adults were compared with those of the 6 young chil-
dren with autoimmune relapses (table e-2), the young
children were more likely to have choreoathetosis
(6/6 vs 0/8, p , 0.01) and decreased level of con-
sciousness (6/6 vs 2/8, p , 0.01). In addition, 3/6
young children developed refractory seizures and sta-
tus epilepticus (2 preceding choreoathetosis) while
only 1/8 in the teenager and adult group had seizures.
MRI with contrast was obtained in 3 young children;
1 showed contrast enhancement and the other 2, who
had the study performed after immunotherapy, did
not show enhancement.
The interval from onset of HSE to relapsing symp-
toms was similar in the teenager and adult group
(median 39 days, range 12–51) and in the young chil-
dren group (median 27 days, range 17–40, p5 0.25),
but the first group had a longer delay in the recognition
of the relapsing symptoms than the young children
Figure 2 Demonstration of brain autoantibodies in a patient with autoimmune relapse post–herpes simplex virus encephalitis
Consecutive sections of rat brain immunostained with CSF of a participant without NMDA receptor (NMDAR) antibodies (A, negative control), a patient with
classical anti-NMDAR encephalitis (B, positive control), and the CSF of patient 9 by the time of herpes simplex virus encephalitis (C) and on day 19 when
relapsing neurologic symptoms due to autoimmune encephalitis occurred (D). The CSF of patient 9 shows a pattern of antibody reactivity typical of NMDAR
but superimposed with diffuse background staining (compare B with D), likely representing disruption of the blood–brain barrier or additional antibodies
against other autoantigens (targets unknown). A similar background staining was noted in the CSF of the other patients; this dirty background usually clears
up during CSF follow-up studies and eventually disappears (e.g., the reactivity becomes clear and indistinguishable from that seen in B; data not shown). In B
and D, the presence of NMDAR antibodies was confirmed with cell-based assay (not shown). Bar 5 500 mm.
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group (interval onset of symptom relapse/antibody
testing 85 days, range 17–296, vs 4 days, range 0–55
in children, p 5 0.037). Moreover, all young children
were promptly treated with immunotherapy, while one
of the adult patients did not receive immunotherapy
and the other 7 were treated with substantial delay
(interval from relapsing symptoms to immunotherapy
in the teenager and adult group 79 days, range 17–
352, vs 4 days, range 0–12, in the young children
group, p 5 0.043).
DISCUSSION The recent identification of antibodies
to NMDAR and other synaptic proteins has provided
a proof of principle to the long-held theory that
relapsing symptoms post-HSE (or choreoathetosis
post-HSE) can be immune-mediated, and has
increased awareness for this complication in children
and adults.5,6,9 In the current study, we report several
novel findings in the age group of adults and teenagers
demonstrating that (1) the main clinical manifestations
are different from those of young children; (2) the
symptom presentation may occur as a relapse of
encephalitis (biphasic course), or in contiguity with
HSE, suggesting progression or recrudescence of
residual deficits after the viral infection; (3) an
immune-mediated pathogenesis is often not suspected,
or is considered late in the course of the disease, likely
explaining substantial delays in immunotherapy; (4) the
brain MRI frequently shows contrast enhancement
during the autoimmune relapse; (5) in addition to
Figure 3 MRI findings in patients with relapsing symptoms post–herpes simplex encephalitis
Axial fluid-attenuated inversion recovery sequences of patients 1 (A, B) and 2 (C, D) during herpes simplex virus encephalitis
(HSE) (A, C) and during relapsing symptoms due to autoimmune encephalitis (B, D). In both cases, there is an interval change
due to areas of encephalomalacia, brain atrophy, and white matter changes. Panels E–H correspond to T1 sequences with
contrast from patient 3 obtained during HSE (E), a few weeks later during relapsing symptoms due to autoimmune enceph-
alitis (F, G), and after symptom improvement (H). Note that the areas of contrast enhancement during autoimmune enceph-
alitis resolved after symptom improvement. Panels I–L correspond to patient 4 during HSE (I, T2; J, T1 with contrast) and
1 year later (K, T2; L, T1 with contrast). In this patient, the relapsing symptoms post-HSE were not recognized as autoim-
mune encephalitis for 1 year; during this year, he did not receive immunotherapy and had persistent symptoms and contrast
enhancement in MRI.
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NMDAR, patients may develop antibodies to GABAAR
or other, unknown, neuronal cell-surface antigens;
and (6) prompt diagnosis and immunotherapy
improve symptoms and favorably affect the quality
of life of patients and families despite persistence of
HSE-related deficits.
The current data confirm that in young children
the most characteristic manifestation of the disorder
is choreoathetosis,4,6,17 which in some patients may
be accompanied or preceded by refractory seizures or
status epilepticus and the most common autoanti-
body is against NMDAR. In contrast, none of the
teenagers or adults developed choreoathetosis; in
these patients, the NMDAR antibodies also predomi-
nated in the antibody repertoire, but some patients
had antibodies against unknown neuronal cell surface
proteins. The novel finding of GABAAR antibodies in
one of the young children with choreoathetosis and
status epilepticus and a previous report demonstrating
dopamine receptor antibodies7 support the concept
that the viral encephalitis triggers an immune
response against a wide number of antigens. Further
support is provided by the reactivity of the CSF or
serum of some patients with live neuronal cultures
even when studies with cell-based assays expressing
all known surface antigens are negative.6 Given that
we have always found that CSF IgG antibodies to
GluN1 associate with anti-NMDAR encephalitis18,19
and these antibodies are pathogenic in models of cul-
tured neurons20 and mice,21 we postulate they con-
tribute to patients’ symptoms. The pathogenic role of
the other antibodies is unclear.
Preliminary data of our ongoing prospective study
in which all patients with HSE are clinically and
immunologically followed after the viral infection
show that 5/20 patients (25%) developed immune-
mediated neurologic symptoms, suggesting that this
complication might be underrecognized. In teenagers
and adults, the problem of syndrome underrecogni-
tion is worse than in younger children given that they
had substantial longer delays in antibody testing
(unless they were part of the prospective study) and
initiation of immunotherapy. The 2 main reasons
for these delays included the type of syndrome, which
in teenagers and adults was less stereotyped (e.g.,
absence of choreoathetosis), and the initial symptom
presentation, which in some patients was not sugges-
tive of a clinical relapse. Indeed, the symptom presen-
tation in most patients of the teenager and adult group
was initially attributed to a progression or recrudes-
cence of residual deficits and therefore not suspected
to be autoimmune nor viral-induced; the clinical inter-
val change noted in the scheduled visits suggested the
autoimmune process. These findings have led to mod-
ification of the protocol to include early follow-up
visits (e.g., 1 month after hospital discharge).
Compared with the brain MRIs obtained during
HSE (which showed mild or absent contrast enhance-
ment), the MRIs obtained during symptom relapse
had intense contrast enhancement that decreased or dis-
appeared after the use of immunotherapy and clinical
improvement. This observation has not been previously
reported and deserves further study with a larger number
of patients in order to assess if contrast-enhancing MRI
is a potential biomarker of the autoimmune response.
An important finding of this study is the symptom
response to immunotherapy. In addition to the remark-
able improvement of the patient shown in figure 1, the
clinical response in other patients was similarly impres-
sive despite their residual deficits caused by the viral
encephalitis. Before the autoimmune relapse, all pa-
tients were collaborative or able to communicate and
carry out some activities of daily living according to the
expected limitations caused by the areas of viral-induced
necrosis (usually affecting short-term memory and lan-
guage). However, this clinical picture contrasted with
that observed during the autoimmune relapse, when
most of the patients were agitated, aggressive, not col-
laborative, some of them with suicidal thoughts, or with
seizures or decreased level of consciousness progressing
to coma. In all but one patient, who improved with
symptomatic treatment, immunotherapy (usually first-
line, such as steroids, IVIg, or plasma exchange) restored
the clinical picture to the baseline deficits, allowing con-
tinuation of rehabilitation or discharge home.
The current findings suggest that patients with
HSE should be carefully followed for any symptom
relapse, worsening of deficits, or development of
behavioral-psychiatric alterations with or without cho-
reoathetosis or abnormal movements. Any of these
symptoms should raise concern for a viral relapse or
an immune-mediated complication. Determination
of CSF and serum neuronal cell surface antibodies
(mainly NMDAR) is a relatively new and important
aid in the diagnosis of immune-mediated relapses
post-HSE, and should be considered in all patients.
If NMDAR antibodies are negative and testing for
other antibodies is not available, a research laboratory
should be contacted for further studies. Meanwhile,
if the CSF PCR for HSV is negative, it seems reason-
able to start these patients with empiric immuno-
therapy (e.g., first-line steroids, IVIg, or plasma
exchange), and depending on the symptom response
and antibody results, more intense therapies such as rit-
uximab considered. The ongoing prospective multi-
center study will clarify whether neuronal cell surface
antibodies may occur without relapsing symptoms
post-HSE, or if there is a titer threshold required for
symptom development. The significance of MRI con-
trast enhancement in the areas previously affected by
HSE, and the identity of additional target autoanti-
gens, should be goals of future studies.
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